Key points from article :
TRexBio, a South San Francisco-based biotech company, has raised $84 million in an oversubscribed Series B financing round to accelerate the development of its inflammation-targeting therapies. This funding will support the clinical development of TRB-061, a novel TNFR2 agonist, aimed at restoring immune homeostasis in human tissues. The company plans to begin Phase 1 clinical trials for TRB-061 in the first half of 2025.
TRexBio specializes in regulatory T cells (Tregs), key immune system regulators essential for managing tissue inflammation and promoting healing. Traditional animal models often fail to replicate human immune dynamics accurately. To address this gap, TRexBio uses a proprietary platform to map human tissue immune regulation, offering precise insights into Treg behavior. This approach enables the identification of new therapeutic targets and a focus on achieving immune balance rather than merely suppressing immune activity.
TRB-061, one of the company’s most advanced programs, selectively targets TNFR2, a receptor expressed in highly suppressive Tregs found in tissues like the skin and gut. By activating these Tregs, TRB-061 aims to regulate immune responses and reduce inflammation in autoimmune and inflammatory diseases.
The funding round was led by Delos Capital, with participation from major investors, including Pfizer Ventures, Johnson & Johnson, and Eli Lilly and Company. The financing will also support the expansion of TRexBio’s broader pipeline of therapies, which address inflammatory and autoimmune conditions and fibrosis. Dr. Eric Huang of Delos highlighted the transformative potential of TRexBio’s therapies in creating a new pillar of care for immune-related diseases.
This research and funding reflect a significant step toward addressing unmet medical needs through innovative, human-focused therapeutic approaches.
